Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00101946

Enrollment

Registered

2005-01-19

Start date

2004-10-31

Completion date

2006-07-31

Last updated

2015-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Keywords

CD, Crohn's Disease

Brief summary

This study will evaluate the effectiveness and safety of the investigational drug 683699 in treating subjects with moderately to severely active CD (Crohn's Disease).

Interventions

DRUG683699

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosed with CD and reconfirmed in previous 2 years by a radiologic or endoscopic assessment including histology. * CDAI (Crohn's Disease Activity Index) score of 220-450 after 1 week of screening. * CRP (C-Reactive Protein) level of \>4mg at screening.

Exclusion criteria

* Significantly abnormal laboratory tests or ECG (electrocardiogram) results. * Current use of an elemental diet or parenteral nutrition. * Clinically significant positive stool culture. * Ongoing neoplastic disease of the bowel. * Bowel perforation other than fistulae. * Has an ileostomy or colostomy. * Fixed symptomatic gastrointestinal (GI) stricture within 6 months or obstructive symptoms within 3 months of screening. * Any bowel resection within 12 months of screening or bowel resection without subsequent demonstration of recurrence of active CD. * More than 100cm of bowel resected. * Non-curative bowel surgery with 2 months of screening. * Symptoms attributed to short bowel syndrome. * Uncontrolled bacterial, viral, or fungal infection or congenital or acquired immunodeficiency. * Women who are pregnant, breast feeding, or planning to become pregnant during the study. Permitted medications: * Less than or equal to 20mg/day oral corticosteroids for at least 4 weeks prior to screening and on stable doses for 2 weeks prior to screening. * Azathioprine and 6-MP (6-Mercaptopurine) stable dose for 3 months prior to screening. * 5-ASA (5-Aminosalicylic acid) stable dose for 1 month prior to screening. Prohibited medications: * Greater than 20mg/day oral corticosteroids, or systemic intravenous corticosteroids, or antibiotics as a treatment for CD within 4 weeks prior to screening. * Cyclosporine or methotrexate during the 2 months prior to screening. * Infliximab or other biological treatments within 3 months prior to screening.

Design outcomes

Primary

Measure	Time frame
Proportion of subjects who are responders at Week 6.	—

Secondary

Measure	Time frame
- Proportion of subjects with response at other timepoints. - Proportion of subjects in remission. - Average rate of response for the CDAI score. - Mean change from baseline in CDAI score Improvement in Quality of Life.	—

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026